Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Modern methods of vaccination have confirmed their high effectiveness in fighting against the pandemic of a novel coronavirus infection. However, the use of various types of vaccines requires studying the effectiveness of the post-vaccination immune response (PIO), first of all, assessing the specificity and amount of production of antibodies to the surface and internal antigens of the SARS-CoV-2 virus, in particular, after the use of the most promising domestic vaccine Gam-Covid-Vac (Sputnik V). In particular, the data on the effectiveness of PVIR (increased antibody level) for the most promising domestic vaccine Gam-Covid-Vac (Sputnik V) need to be confirmed. It is also necessary to evaluate the effectiveness of the laboratory methods used for this purpose. To assess the effectiveness of PVIR, samples of biomaterial (blood serum) obtained on the 2225 day after inoculation of the second component of the vaccine from 202 Sputnik V-vaccinated, not preimmunized subjects, lacking antibodies to SARS-CoV-2 before vaccination, were examined. The levels of IgG and IgM antibodies to the surface and nucleocapsid antigens of the SARS-CoV-2 virus were determined using several semi-quantitative and quantitative methods and reagent kits from national and foreign manufacturers. To assess the diagnostic effectiveness of the methods, a comparative analysis of the specificity and sensitivity of all the laboratory methods used and a data correlation for various quantitative methods (using the Spearman correlation coefficient) between antibodies specific to the full-sized trimerized S-protein and the receptor-binding domain (RBD) of the SARS-CoV-2 S-protein were carried out. During the study, it was determined that all the reagent kits used to study IgG antibodies against SARS-CoV-2 S-protein and S-protein RBD showed maximum (100%) specificity in in the majority subjects (from 186 to 202 samples). The relevance of the data (comparative specificity), both for semi-quantitative and quantitative ELISA as well as for both ILA test systems regarding qualitative characteristics (positivenegative) was also close to the maximum magnitude (98.499.4%). A post-vaccination immune response during Sputnik V vaccination analyzing production of specific IgG antibodies was observed in 98.9% of all vaccinated subjects. IgG antibody range was studied to assess related protective level. Data are presented that a protective level of more than 150 BAU/мл was observed in 59.390.5% of the subjects, above 500 BAU/мл in 22.052.4% of the subjects, depending on the method used and the set of reagents. Based on the data obtained, it is concluded that all the methods and kits of reagents used, including domestically manufactured semi-quantitative tests, can be considered adequate to assess effectiveness of the post-vaccination immune response analyzing production of SARS-CoV-2-specific antibodies.
Modern methods of vaccination have confirmed their high effectiveness in fighting against the pandemic of a novel coronavirus infection. However, the use of various types of vaccines requires studying the effectiveness of the post-vaccination immune response (PIO), first of all, assessing the specificity and amount of production of antibodies to the surface and internal antigens of the SARS-CoV-2 virus, in particular, after the use of the most promising domestic vaccine Gam-Covid-Vac (Sputnik V). In particular, the data on the effectiveness of PVIR (increased antibody level) for the most promising domestic vaccine Gam-Covid-Vac (Sputnik V) need to be confirmed. It is also necessary to evaluate the effectiveness of the laboratory methods used for this purpose. To assess the effectiveness of PVIR, samples of biomaterial (blood serum) obtained on the 2225 day after inoculation of the second component of the vaccine from 202 Sputnik V-vaccinated, not preimmunized subjects, lacking antibodies to SARS-CoV-2 before vaccination, were examined. The levels of IgG and IgM antibodies to the surface and nucleocapsid antigens of the SARS-CoV-2 virus were determined using several semi-quantitative and quantitative methods and reagent kits from national and foreign manufacturers. To assess the diagnostic effectiveness of the methods, a comparative analysis of the specificity and sensitivity of all the laboratory methods used and a data correlation for various quantitative methods (using the Spearman correlation coefficient) between antibodies specific to the full-sized trimerized S-protein and the receptor-binding domain (RBD) of the SARS-CoV-2 S-protein were carried out. During the study, it was determined that all the reagent kits used to study IgG antibodies against SARS-CoV-2 S-protein and S-protein RBD showed maximum (100%) specificity in in the majority subjects (from 186 to 202 samples). The relevance of the data (comparative specificity), both for semi-quantitative and quantitative ELISA as well as for both ILA test systems regarding qualitative characteristics (positivenegative) was also close to the maximum magnitude (98.499.4%). A post-vaccination immune response during Sputnik V vaccination analyzing production of specific IgG antibodies was observed in 98.9% of all vaccinated subjects. IgG antibody range was studied to assess related protective level. Data are presented that a protective level of more than 150 BAU/мл was observed in 59.390.5% of the subjects, above 500 BAU/мл in 22.052.4% of the subjects, depending on the method used and the set of reagents. Based on the data obtained, it is concluded that all the methods and kits of reagents used, including domestically manufactured semi-quantitative tests, can be considered adequate to assess effectiveness of the post-vaccination immune response analyzing production of SARS-CoV-2-specific antibodies.
Determining the efficiency of the principal means of specific immunoprophylaxis in forming thepost-vaccinal immunity against the new coronavirus infection (СOVID‑19) is a very important and topical problem. Solving it involves the evaluation of the efficiency and choosing the laboratory diagnostics technique for an adequate estimation of the nature and the level of thepost-vaccinal immune response (PIR).Research objectives. Evaluating efficiency of the humoral PIR involving theproduction of specific antibodies in patients vaccinated with ‘CoviVac’using quantitative andsemi-quantitative test systems developed by Russian and international companies.Material and methods. The level of antibodies matching the principal known antigens of the SARS-CoV‑2 virus was measured. The probes were taken in a group of 103 persons 22–30 days after vaccination. The techniques used were the principal immunochemical ones (enzymelinkedimmunosorbent assay (ELISA) and chemiluminescent microparticle immunoassay (CMIA)). The nature and the level of the PIR in terms of these antibodies’ production was studied, and the adequacy of the diagnostic techniques applied was evaluated, wherefore the result convergence was studied, and the techniques’ cross-sensitivity and specificity were determined.Results. Insufficient level of PIR in terms of producing antibodies against SARS-CoV‑2 after vaccination with‘CoviVac’was established. The levels of antibodies were found to be not highenough to ensure a reliable immunity against the Covid‑19. However, a highdegree of correlation between the results of different quantitative techniques for measuring theantibodies matching the S-protein and its BRD of the SARS-CoV‑2 virus was determined. Arather high convergence of the results of the quantitative and semi-quantitative techniques usedfor studying this type of antibodies was found.Conclusions. The PR upon the vaccination with the ‘CoviVac’ is characterized by insufficientintensity level in terms of forming the long-living IgG antibodies with surface antigens of SARS-CoV‑2. In particular, the antibody count, which is generally considered capable of ensuringreliable protection, was not reached. Efficiency of the immunochemical testsystems used in this study is high enough and can provide an adequate estimate of the PIR after the vaccination with ‘CoviVac’ .
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.